DCPrime B.V. (DCPrime) is a spin-off company of the VU University Medical Center (VUmc) in Amsterdam, dedicated to developing a novel type of therapeutic vaccines. The company was founded in 2005 by Prof. Dr. Ada Kruisbeek and Prof. Dr. Rik Scheper.
It has become clear that DC-based vaccines can sometimes produce spectacular results in individual patients. Since DC-based vaccines are based on patient-derived DC, however, they pose significant logistical and standardization problems. DCPrime is creating a new type of DC-based vaccines that bypass the problems associated with patient-derived DC vaccines.
Unique Features
DCPrime is the first to test an allogeneic (non-patient-derived, standardized product) DC-based immunotherapy. This is based on its proprietary progenitor DC line, DCOne, and the processes to produce DC from this line. This should combine the expected superior allogeneic stimulation of the immune system, with the power of DC and off-the-shelf product characteristics. Such a standardized product is much more attractive from a production, operational and clinical perspective. Moreover, it concerns a technology platform that allows for different products to be made, each tailored to a specific kind of cancer. As such, DCPrime's DCOne cell line is an immunotherapy platform applicable in a broad range of cancer types.
It has become clear that DC-based vaccines can sometimes produce spectacular results in individual patients. Since DC-based vaccines are based on patient-derived DC, however, they pose significant logistical and standardization problems. DCPrime is creating a new type of DC-based vaccines that bypass the problems associated with patient-derived DC vaccines.
Unique Features
DCPrime is the first to test an allogeneic (non-patient-derived, standardized product) DC-based immunotherapy. This is based on its proprietary progenitor DC line, DCOne, and the processes to produce DC from this line. This should combine the expected superior allogeneic stimulation of the immune system, with the power of DC and off-the-shelf product characteristics. Such a standardized product is much more attractive from a production, operational and clinical perspective. Moreover, it concerns a technology platform that allows for different products to be made, each tailored to a specific kind of cancer. As such, DCPrime's DCOne cell line is an immunotherapy platform applicable in a broad range of cancer types.